LONDON – A funding crisis is threatening the development of new drugs for treating mental illness following the "abrupt" withdrawal by pharma companies from research in the field, coupled with a reduction in public sector investment, according to the European College of Neuropsychopharmacology (ECNP). (BioWorld International)